// App-Quantinova.ai

4560 : Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment Exploratory analyses from JAVELIN Bladder 100.

Researchers

Presenter

  • Joaquim Bellmunt

Principal Investigators

  • Thomas Powles

  • Miguel Angel Climent Duran

  • Srikala S. Sridhar

  • Howard Gurney

  • Nuno Costa

  • Alessandra Di Pietro

  • Bo Huang

  • Shilpa Gupta

  • Petros Grivas

Medical Centers

  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

  • Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom

  • Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Macquarie University Hospital, Sydney, Australia

  • Pfizer, Porto Salvo, Portugal

  • Pfizer Inc, Milan, Italy

  • Pfizer, Groton, CT

  • Cleveland Clinic, Cleveland, OH

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Locations

  • United States

  • United Kingdom

  • Spain

  • Canada

  • Australia

  • Portugal

  • Italy

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02603432

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved